News and Announcements
MedAdvisor – Rapid Growth of Patient Engagement Programs
- Published December 12, 2016 1:40PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
12th December 2016 – ASX Announcement
- Rapid growth of Patient Engagement Programs (PEPs), now with 18 medications part of educational programs, up from 8 medications 12 months ago
- PEPs reaching over 55,000 patients, delivering value to both manufacturers, pharmacies and patients
- MedAdvisor utilised by 9 of Australia’s largest pharmaceutical companies, including, Novartis, Bristol-Myers Squibb, GSK, AstraZeneca and now Pfizer
- PEPs continue to generate recurring revenue, with further growth anticipated as more manufacturers leverage the MedAdvisor platform across its growing patient base
- Healthnotes integration progressing well, with the merged team focused on creating a best in class technology offering
MedAdvisor Limited (ASX: MDR, the Company), Australia’s leading digital medication adherence company, is pleased to provide an update on the rapid growth that its Patient Engagement Programs (PEPs) have achieved throughout 2016.
Consistent with MedAdvisor’s strategy to drive awareness and deliver value for pharmaceutical companies, the Company’s PEP offering is now being utilised by nine of Australia’s largest pharmaceutical companies including Novartis, Bristol-Myers Squibb, GSK, AstraZeneca, and now Pfizer (see announcement dated 8 November 2016). The significant uptake experienced among large pharmaceuticals companies evidences the huge benefits MedAdvisor delivers and demonstrates the global potential for the platform.
To view the full announcement, please click on the button below.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
